Aribio Holdings아리바이오홀딩스
290690 · KOSDAQ · ₩290690 · 아리바이오홀딩스
₩2,620▼ ₩65 (2.42%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩38B | ₩51B | ₩60B | ₩56B | ₩70B |
| Cost of sales | ₩34B | ₩45B | ₩49B | ₩48B | ₩53B |
| Gross profit | ₩4.3B | ₩6.1B | ₩11B | ₩8.3B | ₩17B |
| Operating income | −₩6.7B | −₩6.6B | ₩516M | −₩4.3B | ₩5.1B |
| Net income | −₩7.7B | −₩41B | −₩6.7B | −₩4.3B | ₩4.2B |
| Net income to shareholders | −₩7.7B | −₩41B | −₩6.7B | −₩4.3B | ₩4.2B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩142B | ₩117B | ₩160B | ₩68B | ₩74B |
| Current assets | ₩19B | ₩25B | ₩48B | ₩30B | ₩26B |
| Cash and equivalents | ₩628M | ₩3.2B | ₩22B | ₩4.6B | ₩2.5B |
| Total liabilities | ₩51B | ₩39B | ₩98B | ₩25B | ₩26B |
| Current liabilities | ₩45B | ₩26B | ₩83B | ₩24B | ₩24B |
| Borrowings | ₩36B | ₩31B | ₩82B | ₩9.8B | ₩13B |
| Total equity | ₩91B | ₩78B | ₩62B | ₩43B | ₩48B |
| Shareholders' equity | ₩91B | ₩78B | ₩62B | ₩43B | ₩48B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩2.7B | −₩6.5B | −₩3.7B | ₩16B | −₩6.3B |
| Capital spending | ₩683M | ₩231M | ₩622M | ₩392M | ₩1.5B |
| Free cash flow | −₩3.4B | −₩6.7B | −₩4.3B | ₩15B | −₩7.9B |
| Dividends paid | — | — | ₩413M | ₩413M | ₩408M |
Consolidated where available. Amounts in won.
Also known as: Aribio Holdings / 아리바이오홀딩스 / 290690 / KRX:290690
Source: KRX statistical information